- Home
- NTLA vs BHLB Comparison
NTLA vs BHLB Comparison
Compare NTLA & BHLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTLA
- BHLB
- Stock Information
- Founded
- NTLA 2014
- BHLB 1846
- Country
- NTLA United States
- BHLB United States
- Employees
- NTLA N/A
- BHLB N/A
- Industry
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- BHLB Banks
- Sector
- NTLA Health Care
- BHLB Finance
- Exchange
- NTLA Nasdaq
- BHLB Nasdaq
- Market Cap
- NTLA 1.2B
- BHLB 1.1B
- IPO Year
- NTLA 2016
- BHLB 2000
- Fundamental
- Price
- NTLA $12.06
- BHLB $26.50
- Analyst Decision
- NTLA Buy
- BHLB Buy
- Analyst Count
- NTLA 20
- BHLB 4
- Target Price
- NTLA $32.30
- BHLB $33.88
- AVG Volume (30 Days)
- NTLA 4.2M
- BHLB 537.9K
- Earning Date
- NTLA 08-07-2025
- BHLB 10-23-2025
- Dividend Yield
- NTLA N/A
- BHLB 2.75%
- EPS Growth
- NTLA N/A
- BHLB 404.16
- EPS
- NTLA N/A
- BHLB 2.56
- Revenue
- NTLA $52,857,000.00
- BHLB $438,910,000.00
- Revenue This Year
- NTLA $8.32
- BHLB $30.73
- Revenue Next Year
- NTLA N/A
- BHLB $79.15
- P/E Ratio
- NTLA N/A
- BHLB $10.22
- Revenue Growth
- NTLA 14.99
- BHLB 35.24
- 52 Week Low
- NTLA $5.90
- BHLB $22.27
- 52 Week High
- NTLA $23.76
- BHLB $32.36
- Technical
- Relative Strength Index (RSI)
- NTLA 60.10
- BHLB 59.31
- Support Level
- NTLA $11.29
- BHLB $25.90
- Resistance Level
- NTLA $12.46
- BHLB $27.43
- Average True Range (ATR)
- NTLA 0.56
- BHLB 0.61
- MACD
- NTLA 0.12
- BHLB 0.09
- Stochastic Oscillator
- NTLA 84.85
- BHLB 62.87
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
About BHLB Berkshire Hills Bancorp Inc.
Berkshire Hills Bancorp Inc is a holding company. It provides Commercial Banking, Retail Banking, Consumer Lending, Private Banking and Wealth Management services.